Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
1973 1
1985 1
1988 1
1989 2
1991 4
1992 1
1993 3
1994 2
1995 1
1996 3
1998 1
2000 2
2001 5
2002 2
2003 1
2004 3
2005 4
2006 1
2007 1
2008 1
2009 1
2010 1
2011 3
2012 1
2013 1
2014 4
2015 6
2016 4
2017 3
2018 4
2019 11
2020 11
2021 2
2022 6
2023 7
2024 3

Text availability

Article attribute

Article type

Publication date

Search Results

100 results

Results by year

Filters applied: . Clear all
Page 1
Cardiomyopathies in children: An overview.
Tsatsopoulou A, Protonotarios I, Xylouri Z, Papagiannis I, Anastasakis A, Germanakis I, Patrianakos A, Nyktari E, Gavras C, Papadopoulos G, Meditskou S, Lazarou E, Miliou A, Lazaros G. Tsatsopoulou A, et al. Hellenic J Cardiol. 2023 Jul-Aug;72:43-56. doi: 10.1016/j.hjc.2023.02.007. Epub 2023 Mar 3. Hellenic J Cardiol. 2023. PMID: 36870438 Free article. Review.
The annual incidence of 1 per 100,000 children appears higher during the first two years of life. Dilated and hypertrophic cardiomyopathy phenotypes share an incidence of 60% and 25%, respectively. Arrhythmogenic right ventricular cardiomyopathy (ARVC), restr …
The annual incidence of 1 per 100,000 children appears higher during the first two years of life. Dilated and hypertrophic cardiom …
Obstructive Hypertrophic Cardiomyopathy and Takotsubo Syndrome: How to Deal With Left Ventricular Ballooning?
Citro R, Bellino M, Merli E, Di Vece D, Sherrid MV. Citro R, et al. J Am Heart Assoc. 2023 Nov 7;12(21):e032028. doi: 10.1161/JAHA.123.032028. Epub 2023 Oct 27. J Am Heart Assoc. 2023. PMID: 37889174 Free PMC article. Review.
More recently, a second cause has emerged: that in some patients with underlying hypertrophic cardiomyopathy, left ventricular ballooning is caused by the sudden onset of latent left ventricular outflow tract obstruction. ...
More recently, a second cause has emerged: that in some patients with underlying hypertrophic cardiomyopathy, left ventricular …
Evaluation of Hypertrophic Cardiomyopathy: Newer Echo and MRI Approaches.
Habib M, Hoss S, Rakowski H. Habib M, et al. Curr Cardiol Rep. 2019 Jun 26;21(8):75. doi: 10.1007/s11886-019-1173-1. Curr Cardiol Rep. 2019. PMID: 31243594 Review.
PURPOSE OF REVIEW: This review discusses the basic and evolving echocardiographic and cardiac magnetic resonance (CMR) approaches in the diagnosis and management of patients with hypertrophic cardiomyopathy (HCM). RECENT FINDINGS: Newer imaging technologies and tech …
PURPOSE OF REVIEW: This review discusses the basic and evolving echocardiographic and cardiac magnetic resonance (CMR) approaches in the dia …
Syncope in hypertrophic cardiomyopathy (part I): An updated systematic review and meta-analysis.
Mascia G, Crotti L, Groppelli A, Canepa M, Merlo AC, Benenati S, Di Donna P, Della Bona R, Soranna D, Zambon A, Porto I, Olivotto I, Parati G, Brignole M, Cecchi F. Mascia G, et al. Int J Cardiol. 2022 Jun 15;357:88-94. doi: 10.1016/j.ijcard.2022.03.028. Epub 2022 Mar 15. Int J Cardiol. 2022. PMID: 35304190 Review.
AIMS: To describe the proportion of patients with syncope among those affected by hypertrophic cardiomyopathy (HCM) and the relevance of syncope as risk factor for sudden cardiac death and life-threatening arrhythmic events. ...Syncope was reported in 15.8% (3.452 o …
AIMS: To describe the proportion of patients with syncope among those affected by hypertrophic cardiomyopathy (HCM) and the re …
Mitral Valve Disease in Hypertrophic Cardiomyopathy:Evaluation and Management.
Jain CC, Newman DB, Geske JB. Jain CC, et al. Curr Cardiol Rep. 2019 Oct 31;21(11):136. doi: 10.1007/s11886-019-1231-8. Curr Cardiol Rep. 2019. PMID: 31673812 Review.
PURPOSE OF REVIEW: To discuss the critical role of the mitral valve (MV) in the pathophysiology of obstruction in hypertrophic cardiomyopathy (HCM), evaluation of the MV in HCM, the impact of MV characteristics on treatment in HCM, and management of the MV at the ti …
PURPOSE OF REVIEW: To discuss the critical role of the mitral valve (MV) in the pathophysiology of obstruction in hypertrophic car …
Thirty-year outcome in children with hypertrophic cardiomyopathy based on the type.
Tsuda E, Ito Y, Kato Y, Sakaguchi H, Ohuchi H, Kurosaki K. Tsuda E, et al. J Cardiol. 2022 Dec;80(6):557-562. doi: 10.1016/j.jjcc.2022.07.016. Epub 2022 Aug 10. J Cardiol. 2022. PMID: 35961804 Free article. Review.
BACKGROUND: We reviewed the long-term outcome of children with hypertrophic cardiomyopathy (HCM) based on the type. METHODS: We reviewed the medical records of 100 patients (male 54 female 46) with HCM at our hospital between 1977 and 2015. ...RESULTS: The age at th …
BACKGROUND: We reviewed the long-term outcome of children with hypertrophic cardiomyopathy (HCM) based on the type. METHODS: W …
Cardiac Amyloidosis: Updates in Imaging.
Chacko L, Martone R, Cappelli F, Fontana M. Chacko L, et al. Curr Cardiol Rep. 2019 Aug 2;21(9):108. doi: 10.1007/s11886-019-1180-2. Curr Cardiol Rep. 2019. PMID: 31375984 Free PMC article. Review.
RECENT FINDINGS: Advances in imaging have led to earlier identification, improved diagnosis of CA and higher discriminatory power to differentiate CA from other hypertrophic phenocopies. The application of cardiac magnetic resonance imaging (CMR) has led to a deeper unders …
RECENT FINDINGS: Advances in imaging have led to earlier identification, improved diagnosis of CA and higher discriminatory power to differe …
Review of recent advances in the management of hypertrophic cardiomyopathy.
Cao Y, Zhang PY. Cao Y, et al. Eur Rev Med Pharmacol Sci. 2017 Nov;21(22):5207-5210. doi: 10.26355/eurrev_201711_13841. Eur Rev Med Pharmacol Sci. 2017. PMID: 29228435 Free article. Review.
Hypertrophic cardiomyopathy (HCM) is a complex but common monogenic cardiovascular disorder characterized by unexplained non dilated left ventricular (LV) thickening in the absence of another cardiac or systemic disease. ...
Hypertrophic cardiomyopathy (HCM) is a complex but common monogenic cardiovascular disorder characterized by unexplained non d …
New Era: Mavacamten for Obstructive Hypertrophic Cardiomyopathy.
Woodland M, Al-Horani RA. Woodland M, et al. Cardiovasc Hematol Agents Med Chem. 2023;21(2):78-83. doi: 10.2174/1871525721666221019095218. Cardiovasc Hematol Agents Med Chem. 2023. PMID: 36278454 Free PMC article. Review.
Obstructive hypertrophic cardiomyopathy results from asymmetric septal hypertrophy, which eventually obstructs the outflow of the left ventricle. Obstructive hypertrophic cardiomyopathy is linked to mutations in genes that encode for sarcomere proteins …
Obstructive hypertrophic cardiomyopathy results from asymmetric septal hypertrophy, which eventually obstructs the outflow of …
Pharmacotherapy for the treatment of obstructive hypertrophic cardiomyopathy.
Spoladore R, Fragasso G, Pannone L, Slavich M, Margonato A. Spoladore R, et al. Expert Opin Pharmacother. 2020 Feb;21(2):233-242. doi: 10.1080/14656566.2019.1702023. Epub 2020 Jan 1. Expert Opin Pharmacother. 2020. PMID: 31893930 Review.
Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading cause of sudden cardiac death as well as a prevalent cause of heart failure and stroke. ...
Introduction: Hypertrophic cardiomyopathy (HCM) is one of the most common genetic heart diseases and represents a leading caus …
100 results